1 2	Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Systematic review of the literature
3	L v
4	Lisa L. Liu <sup>1,2,#</sup> , Marcus Skribek <sup>1,2</sup> , Ulrika Harmenberg <sup>1,2</sup> , Marco Gerling <sup>1,3,#</sup>
5	
6	<sup>1</sup> Theme Cancer, Karolinska University Hospital, 17176 Solna, Sweden
7	<sup>2</sup> Department of Oncology-Pathology, Karolinska Institutet, 17176 Solna, Sweden
8	<sup>3</sup> Department of Bioscience and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden
9	
10	<sup>#</sup> Corresponding authors:
11	Lisa L. Liu Burström, MD, PhD, email: lisa.liu@ki.se
12	Marco Gerling, Dr. med, email: marco.gerling@ki.se
13	
14	Abstract
15	Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related
16	adverse events (irAEs). As oncological indications for ICIs widen, their rare side effects
17	become increasingly visible in clinical practice and impact therapy decisions.
18	Here, we provide a systematic review of the literature of CRS and related life-
19	threatening side effects of ICI treatment, such as hemophagocytic lymphohistiocytosis
20	(HLH). We searched Medline, Embase, and the Web of Science Core Collection from
21	inception until October 2021 for reports on CRS, cytokine storm, macrophage activation
22	syndrome, HLH, and related hyperinflammatory disorders in patients with solid cancers
23	receiving ICIs. We found $n = 1866$ articles, which were assessed for eligibility independently
24 25	by two examiners. Of those, $n = 49$ articles reporting on $n = 189$ individuals were eligible for
25 26	review. We found that the median time from last infusion to the occurrence of CRS/HLH was
20 27	approximately nine days, while the onset of symptoms varied from immediately after infusion to one month after treatment. Most patients were treated with either corticosteroids
27	or the anti-interleukin 6 (IL-6) antibody tocilizumab, and although the majority of patients
28 29	recovered, a few cases were fatal. Concomitant IL-6 and ICI treatment was reported as
30	beneficial for both the antitumoral effect and for limiting side effects. Data from international
31	pharmacovigilance databases underscored that ICI-related CRS and HLH are rare events, but
32	we identified significant differences in reported frequencies, which might suggest substantial
33	underreporting.
34	The results from this first systematic review of CRS/HLH due to ICI therapy highlight
35	that life-threatening systemic inflammatory complications of ICIs are rare and non-fatal in the
36	majority of patients. Limited data support the use of IL-6 inhibitors in combination with ICIs
37	to augment the antitumoral effect and reduce hyperinflammation.
38	
39	
40	
41	
42	

43

### 44 Introduction

45 Immune checkpoint inhibitors (ICIs) have become important therapeutic options for various 46 tumor types. ICIs are associated with specific toxicities, commonly referred to as immune-47 related adverse events (irAEs), which can lead to treatment interruption or discontinuation. 48 International guidelines aid clinicians in the diagnosis and management of relatively common 49 irAEs, such as skin rashes, colitis, thyroiditis, and pneumonitis<sup>1,2</sup>. However, the increasing volume of patients treated with ICIs is starting to reveal less common side effects, including 50 51 systemic hyperinflammatory syndromes. Nonspecific systemic inflammatory reactions to 52 ICIs, such as self-limiting fever or skin rashes during or shortly after infusion<sup>2</sup>, need to be 53 distinguished from severe, persistent, and potentially life-threatening conditions such as 54 cytokine release syndrome (CRS) and hemophagocytic lymphohistiocytosis (HLH)/macrophage-activation syndrome (MAS)<sup>3</sup>. Due to their severity, these irAEs are of 55 56 particular clinical importance and require a decision on continuation of ICI treatment, for 57 which evidence is lacking. Because of their rarity, hyperinflammatory syndrome are incompletely captured in randomized clinical trials with ICIs<sup>4,5</sup>, and not yet discussed in 58 59 irAE guidelines<sup>1,2</sup>. Hence, real-world data and case reports of rare irAEs are needed to 60 understand their frequency and severity, and to improve clinical management.

61 In cancer therapy, CRS is best understood in the context of chimeric antigen receptor 62 (CAR) T cell therapies, where it occurs in a substantial proportion of patients at different levels of severity<sup>6</sup>. CRS is believed to be mainly driven by T cell-derived interferon gamma 63 64 (IFN- $\gamma$ ), which stimulates macrophages to produce various pro-inflammatory substances including interleukin 6 (IL-6) and tumor necrosis factor alpha  $(TNF-\alpha)^7$ . Therapeutically, IL-65 66 6 inhibition with specific anti-IL-6 receptor antibodies, such as tocilizumab, has proven highly effective against CRS, reflected by the US Federal Drug Agency's approval of 67 tocilizumab for CAR T cell-induced CRS<sup>8</sup>. This is important because IL-6 inhibition could 68 allow for the continuation of any treatment associated with mild CRS<sup>9</sup>. 69

HLH is an umbrella term for life-threatening hyperinflammatory conditions with supramaximal activation of the immune system. For the diagnosis of HLH, the HLH-2004 diagnostic criteria are frequently used, although they were developed for the pediatric population<sup>3</sup>. The criteria include clinical features such as fever and splenomegaly, as well as laboratory findings such as cytopenias, hypertriglyceridemia, hyperferritinemia, evidence of hemophagocytosis, and the absence of natural killer (NK) cell activity<sup>3</sup>. More recently, the

HScore, which includes similar criteria to HLH-2004, was developed to estimate the probability for reactive HLH in adults with inflammatory syndromes<sup>10</sup>. Genetic analyses from pediatric patients have revealed a wide variety of predisposing variants that presumably play a role for different immune cell types, suggesting that HLH-related conditions represent a complex disease continuum<sup>11</sup>.

81 Reports on hyperinflammatory syndromes due to ICI treatment have started to emerge 82 during recent years, and have suggested that these are relatively rare, but potentially lifethreatening events<sup>12</sup>. Both HLH and CRS can be fatal by causing hypotension, capillary leak 83 syndrome, and consequently organ dysfunction<sup>7</sup>. Because of the potential risk of increasing 84 85 the severity of CRS/HLH upon repeated exposure to a particular trigger, suspicion of these 86 hyperinflammatory syndromes in clinical practice most often leads to treatment cessation. 87 Hence, a better understanding of this complex disease spectrum in the context of ICI 88 treatment is needed to guide decision-making on treatment continuation and optimal 89 management.

90 To set the stage for a more evidence-based approach to CRS, we conducted a 91 systematic review of the literature, in which we identify n = 49 articles on n = 189 patients 92 with hyperinflammatory syndromes due to ICIs. The results reveal that most patients with 93 CRS/HLH recover and that a fatal outcome is rare. In addition, the literature reveals that 94 corticosteroids and IL-6 inhibition may provide effective therapies. Extrapolating from 95 preclinical data, which we review in brief, we posit that rechallenging with ICIs after 96 CRS/HLH has been controlled should be considered at least in patients with mild 97 hyperinflammatory ICI side effects who are expected to benefit from ICI treatment. Recent 98 data suggest that ICIs in combination with IL-6 antagonists may boost the antitumoral effect, 99 while simultaneously protecting from severe irAEs, which makes ICIs in combination with 100 IL-6 inhibition an attractive option for rechallenge that warrants further research.

101

## 102 Methods

103

## 104 Systematic review

105 We performed a systematic search for published reports on CRS, HLH and related 106 hyperinflammatory diseases in MEDLINE, Embase, and the Web of Science databases as of 107 October 2021. The search strategies were designed in collaboration with the Karolinska

Institute library and are included as Supplementary Figure 1. Deduplication was performed
as previously described<sup>13</sup>.

110 Additional manual searches were performed based on the lists of references in the 111 eligible studies, and a reduced set of keywords in the MEDLINE database only, as of June 13th 2022. Inclusion criteria for abstract review were assessed independently by two 112 113 reviewers (LLL and MG) and defined as follows: (1) report on any hyperinflammatory 114 syndrome (CRS, HLH, MAS, or any indication of these or related systemic syndromes) on 115 human patients with solid tumors, (2) reported use of any ICI at any time of the treatment, (3) 116 case series or case reports, i.e. no randomized-controlled trial (RCT), unless explicitly stated 117 that CRS/HLH/MAS or any other hyperinflammatory syndrome was reported, (4) articles in 118 English, Swedish, Chinese or German. LLL and MG agreed on article inclusion by discussing 119 the articles for which the initial decision on inclusion differed. For all eligible articles, the 120 full-text was downloaded by LLL or MG. Data were extracted by either LLL, MS, or MG, 121 and all authors convened to agree on final inclusion. As the majority of the included studies 122 were case reports on rare events, no further criteria for study quality assessment were applied 123 and the risk for bias was not assessed. The systematic review was not preregistered.


124

### 125 **Results**

## 126

## 127 Systematic review

To chart our current knowledge of hyperinflammatory syndromes, such as CRS and HLH, as rare side effects of treatment with ICIs, we conducted a systematic review of the literature housed in the major medical databases as of October 2021. In addition, we manually updated the list of eligible studies as of 13<sup>th</sup> June 2022. **Supplementary Figure 2** presents the PRISMA reporting chart for the study.





Supplementary Figure 2: PRISMA 2020 flow diagram of the study.

136

137 We identified a total of n = 49 articles, reporting on n = 189 patients treated in the 138 USA, the UK, Switzerland, Spain, Poland, Lebanon, Japan, Israel, Germany, France, China, 139 Canada, Australia, and Singapore (**Table 1**). Of these studies, n = 45 reports were on n = < 5140 individual patients (comprising a total of n = 56 individuals), while n = 4 studies reported 141 case series or data from queries of pharmacovigilance databases (**Table 1**). Definitions of 142 CRS/HLH varied significantly between reports, and retrospective diagnostic assessment was 143 not possible due to partially incomplete and heterogeneous clinical data. Therefore, we used 144 the respective authors' assessment of the hyperinflammatory condition as CRS, HLH, or 145 related hyperinflammatory diseases for further analysis. The earliest published report was from 2016<sup>12</sup>. 146

147 The ICIs used included pembrolizumab (n = 21 studies) and nivolumab (n = 11148 studies) as single agents, combined treatment with ipilimumab and nivolumab (n = 13), and, 149 less frequently (n = 2 studies each), ipilimumab, sintilimab or atezolizumab monotherapy, 150 and cemiplimab (n = 1). Often, ICIs were combined either with chemotherapeutical agents or 151 other anticancer drugs, such as TKIs (i.e. cabozantinib or dabrafenib/trametinib), or drugs 152 that were used prior to development of the hyperinflammatory syndrome(s).

153 In the individual reports, n = 15 patients were diagnosed with CRS, n = 34 with HLH, 154 and n = 6 were described as having related hyperinflammatory conditions such as capillary 155 leak syndrome with high fever, or systemic inflammatory response syndrome (SIRS). The 156 most frequently reported underlying malignancies in individual case reports were malignant 157 melanoma (n = 21 individual reports) and lung cancer (n = 14 individual reports). The 158 average age of the patients in the individual reports was 59 years. In individual reports that 159 reported the patients' sex, n = 35 patients were males, and n = 20 patients were females. The 160 highest frequencies of male patients were also reported in the largest case series from two centers in Singapore<sup>14</sup> (n = 18 males, n = 7 females), and in a World Health Organization 161 (WHO) pharmacovigilance database queried for HLH<sup>15</sup> (n = 29 males, n = 9 females) and 162 CRS, respectively<sup>16</sup> (n = 34 males, n = 21 females). Most studies (n = 46 studies out of 49) 163 164 comprised data on patients with metastatic disease (Table 1). Time from ICI infusion to onset 165 of symptoms varied from hours to one month, with a median of n = 9 days. In total, n = 42166 studies on n = 56 individual patients (75%) reported recovery from ICI-induced irAEs, while 167 n = 5 cases (out of 56, corresponding to 8.9%) were fatal. Of those, n = 3 cases were reported 168 to have HLH, and n = 2 had CRS, as per the authors' assessment. Overall, n = 42 patients 169 from individual reports were reported to have recovered from their hyperinflammatory

170 complications. Reports from pharmacovigilance data were incomplete for outcome data; a

171 study including n = 25 patients from Singapore reported n = 3 fatal cases (0.12 %).

Treatments for CRS/HLH varied significantly, and included different types of corticosteroids in almost all cases, and tocilizumab in n = 14 cases. Various other drugs were used in some patients, including etoposide in combination with dexamethasone, an established HLH treatment<sup>17,18</sup>, as well as intravenous immunoglobulins, plasmapheresis, mycophenolate mofetil, and tacrolimus. Often, these were combined, at least initially, with antibiotic therapy because of suspected sepsis (**Table 1**).

## 179 Table 1: Studies retrieved in systematic review

Authors <sup>ref</sup> <u>Publication</u> <u>year</u> <u>Country</u>	<u>Study title</u>	Type of malignancy	<u>No. of</u> patients with CRS	<u>Age</u> <u>&amp;</u> <u>Sex</u>	<u>Tumor</u> <u>burden</u> (stage)	<u>Antibody used</u>	<u>Additional therapy</u>	<u>Main complication</u> ( <u>CRS, HLH, other,</u> <u>as assessed by the</u> <u>authors)</u>	<u>Cycle of ICI</u> <u>treatment</u> <u>prior to</u> <u>CRS/HLH</u>	<u>Time from</u> infusion to <u>symptoms</u> (in days)	<u>Main symptoms</u>	Intervention (steroids, 11-6, other)	<u>CRS/HLH-</u> <u>specific</u> outcome after intervention	<u>Rechailenge ICI</u>	<u>Tumor-</u> <u>specific</u> outcome	<u>Com ments</u>
Sharma et al. <sup>12</sup> 2016 USA	Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors.	'Progress ive lung cancer'	12		N/A	N ivo lu ma b		SIRS	Unclear		'One or more of the following - fever, tachycardia, hypotension, organ failure occurring 1-2 days to weeks after immunotherapy.'	Steroids, tocilzumab	Unclear	Unclear	Unclear	Presented as poster; no detailed description of individual cases in published abstract.
El Rassy et al. <sup>19</sup> 2017 Lebanon	Diffuse ede ma suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab	Lung squamous cell carcinoma	1	62 M	Metastatic (stage IV)	Pe mbro lž uma b		CRS	7	1	"Fatigue, persistent low-grade fever and a nacute onset of diffuse swelling involving [] limbs and abdomen. [] pain sensation on exertion in both hands and legs."	Furose mide for ede ma, then steroids.	Recovery	Yes, up to at least 13 cycles.	Unclear	
Shah et a 1. <sup>20</sup> 2017 USA	Pembrolizumab associated hemophagocytic lymphohistiocyt osis	Bladder	1	76 M	Metastatic	Pe mbro lz uma b		HLH	9 months of therapy	U nclear	Fatigue, fever. Sinus tachycardia, pallor, maculo pau Jus rash, and spleno megaly. Pancytopen a. Acute renal failure. Hyperferitinemia and hyperfibrino genemia. Increased soluble IL- 2R.	E topo side, stero ids	Unclear	Unclear	CR	
Rotz et a l. <sup>21</sup> 2 017 USA	Severe cytokine release syndrome in a patient receiving PD-1-directed therapy	Sarco ma	1	29 F	Metastatic	Nivoluma b	Pazo panib	CRS	2	4	Fatigue, myalgias, fever, diffuse macub papular rash, ence phab pathy. Fever, tachy ardia, hypotension, desaturation and disorientation. Thrombocytopenia, lactic acidoss, acute kidney and liver injury. Abnormal coagulat on studies. Elevated CRP. Elevated leves of IL. 6, IL-8, IL-10, FN-Y.	IV fluids, sterods, broad- spectrum ABs, tocilizumab.	Recovery	No	Unclear	
Urose vic- Ma iwa ld et al. <sup>22</sup> 2017 Switzerland	Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti- PD-1 therapy for melanoma	Malignant melano ma	2 (1)	45 F	Metastatic (stage IV)	Pe mbro lž uma b	Dabrafe nib/tra metinib after ICI progress. Side effects, switched instead to vemurafenib/ cobimetinib	SIRS		28	Fever, chilb, fatigue. Hypotens ion (18/26 mm Hg), tachycardia, anuria.	Broad- s pect rum ABs, steroids	Recovery	No, but rechallenge with ve murafenib/c o bimetini b did not result in recurrence		

Cont. Urosevic- Maiwaldet al.		Malignant melano ma	2 (2)	48 F	Metastatic (stage IV)	Pembrolit umab	Vernurafen ib and co bimet in ib after ICI progress	'hypersens it ivity syndrome' or DRESS	Unclear	8	Face swelling (including eyes and lips) and a diffuse pruritic eruption, composed of erythematous and violaceous mac u les and papules. Hypotension, tachycardia and fever >33°C.	Stero ids	Recovery	No	Unclear, but PD after around 7 months	
Takeshita et al. <sup>23</sup> 2017 Japan	Co incidence of immunotherapy- associated hemophagocytic syndrome and rapid tumor regression	Squamous non-small cell lung cancer	1	63 F	Metastatic (stage IV)	N ivo lu ma b		CRS	2	25	Severe general fat gue and high- grade fever	Methylpredniso lone (1000 mg/day, 3 days, then prednisobne.	Recovery	No	Regression	
<b>Michotet</b> al. <sup>24</sup> 2018 France	Fever reaction and haemophagocyti c syndrome induced by im mune checkpoint inhibitors	Melanoma	1	52 F	Metastatic (stage IV)	Ipilimu ma b	Previously & cycles of pembro lizu mab, then cerebral stereotactic radiotherapy for a brain metastasis, then ipilimumab.	HLH	1 (8 pembrolitu- mab)	Initial symptoms unclear, fulminant disease 8 weeks after the last dose of ipilimumab	Initially grade 3 hepatitis, 'fever with pancytopenia and disseminated intravascular coagulation 8 weeks after the last ipilimumab cycle.'	Steroids, etoposide	Death from bra in hemorrhage at metastatic site.	No	Unclear	
Sadaatet al. <sup>25</sup> 2018 USA	He mop hagocytic lym pho histiocyt osis with im munot hera py: brief review and case report	Malignan t melano ma	1	58 M	Metastatic	Pembroliz umab		HLH	6	31	Fever, upper normal seed spken, anemia, thrombocytopenia, hyperfrigk/ceridemia, reduced NK cell act Nity and elevated sCD163 levels. Nausea, arthragia. Elevated LDH.	Stero ids	Recovery	No	CR for 1 year, then relapse.	
Hantelet al. <sup>26</sup> 2018 USA	Severe hemophagocytic lymphohatiocyt osis in a melano ma patient treated with ipilimumab + nivolumab	Malignant melano ma	1	35 F	Metastatic	Ipilimu ma b/nivo l u ma b		нцн	'Rece ived first doses'	21	Pallor, jaundice, tachycardia. Spieno megaly. Hypotension. Anema. thrombocytopena. Elevated DH and CRP. Low haptoglobin. Hyperferrtielycendemia. Low Trallor.	IV fluids, stenoids.	Recovery	No	CR	Previously progressed on adjuvant ipilimu mab.
Satzger et al. <sup>27</sup> 2018 Germany	Treat ment- related hemophagocytic lymphohistiocyt osis secondary to checkpoint inhibition with nivoluma b plus ipilimuma b	Malignant melano ma	1	26 F	Metastatic	lpilimu mab/nivo l u mab		HLH	4	7	and elevated (D25) Increased liver function tests, fever, Elevated IL-2R, bilirubin, hyperferritinemia, hypofibrinogenemia.	Steroids, mycophenolate mofetil.	Recovery	No	CR	
Shah et al. <sup>28</sup> 2018 USA	A Case of Epstein-Barr Virus-Related He mophagocytic Lymphohistocyt osis in Associatio MWth Pembrolizumab Therapy	Metastatic bladder cancerand thymoma	1	75 M	Metastatic	Pembrolž umab		HLH	Unclear	Unclear	Fever, fat gue, and acute onset pancytopenia. Elevated ferritin, low fibrinogen, spleno megaly, elevated soluble CD25, and decreased natural killer cell acutvity. Hemophagocytosis.	Unclear	Unclear	Unclear	Unclear	Active EBV infection at the same time.

Sasakiet al. <sup>29</sup> 2018 Japan	He mo phago cytic lym phoh bit locyt osia associated with dabrafe nib and tra metinib com bination thera py following pembrolizumab ad ministration for ad wa need me la no ma	Malignant melano ma	1	60 F	Metastatic (stage IV)	Pe mbro iz uma b	Dabrafenib/trametinib after ICI progress	HLH	'1 month after last ICI'	13	Fever, hepatosplenomegaly, and enythema mult forme-like targetoid lesions all over the body. Pancytopenia, hyperferritinemia, increased liver enzyme leves, and coagulaton abnormalities.	Stero ids	Recovery	No, but rechallen ged with TKI, no HLH.	PR	Sequential TKI and ICI
Laderian and Koehn <sup>30</sup> 2019 USA	Association of Hemophagocytic Lymphohistiocyt osis and Programmed Death 1 Checkpoint Inhibitors	T h ymic carcino ma	1	49 M	Metastatic (stage IV)	Pe mbro liz uma b	'Multiagent che motherapy' prior to ICI treatment.	HLH	Several over the course of one year, unspecified.	Unclear	Gradually worsening pancytopenia, hemophagocytosis on bone marrow exam, no signs of viral infection as a cause for HLH.	Unclear	Deceased	Unclear	'Clinical benefit'	
Kogure et al, <sup>32</sup> 2019 Japan	Cyto kine Release Syndrome with Pseudo progressi on in a Patient with Advanced Non-Smail Cell Lung Cancer Treated with Pembro lizumab	Lung ade noca reino ma	1	67 M	Locally advanced (IIIB)	Pe mbro lz umab		CRS	1	2	Fever, tachycardia, hypotension.	Stero ids	Recovery	Yes	Pseudopro gression, after 3 cycles of pembrolizu mab PR, continuous treatment with pembrolizu mab, unclear how may cycles> near CR.	
Oda et al. <sup>22</sup> 2019 Japan	First Case of Cyto kine Release Syndrome after Nivo lumab for Gastric Cancer	Gastric adenocarcinoma	1	43 M	Metastatic	N ivo lu ma b		CRS	1	8	'Fever (39.0°C), tachycardia, appetite loss, malaise.'	Prednisobne, then methylpredniso lone, then mycophenolate mofetil.	Death 'from gastric cancer.'	No	PD	
Noseda et al. <sup>19</sup> 2019 France, Japan, Germany, Switzerland, Canada, USA	Hae mophagocyt i c lym pho hit locyt osis in patients treated with in mune c heckpo int inhibitors: ana lysis of WHO glo bal dara base of ind lividua i case safet y reports	Me la no ma, lung cancer, bladder cancer, renal cell carcino ma, Hodgkin's disease; transitional cell carcinoma, gastric ade nocarcino ma, thymo ma, T-ALL	38	29 M 9 F		Ipilimumab, nivolumab, pembroizumab, atezoizumab, atezoizumab, atezoizumab, and combinations of the above.	Antineo plastic drugs in 2 cases, antibacterial drugs in 2 cases.									Reports 34 cases of HLH from an international pharmacovigi lance database; of note, the frequency of HLH per treated case varies per country from 0.03% (USA) to 0.4%
Lo renz et al. <sup>23</sup> 2019 Germany	He mop hagocytic lym pho hist locyt osis second ary pembro lizuma b treatment with insufficient response to high dose steroids	Prostate	1	68 M	Castration- resistant, metastatic (not further specified)	Pembrolz umab	ADT and enzalutamide	HLH	Unclear	Unclear	Fever, hepatospheno megaly, pancytopenia, hyperferritinemia, elevated serum siL- 2 R hypertriglyceridemia, hypofibrinogenemia, elevated liver enzymes. Hemophagocytosis.	Steroids, d aily plas mapheres is , cyclos por in A, etoposide, tacrolimus .	Recovery	No	CR	(France).

Okawa et al. <sup>34</sup> 2019 Japan	Pembroizumab induzed Autoimmune Hemoiytic Anemia and Hemophagocytic Lymphoihstiocyt osis in Non- smail Cell Lung Cancer	Lung squamo us celi carcinoma	1	78 M	Locally advanced (IIIB)	Pe mbro là uma b		HLH	1	10	Anemia, increased total and indirect bilirubin, reticulocytes and LOH. Autoimmune hemolytic anemia. Fatigue, fever. Jaundice. Leukocytosis. Serum sill-2R elevation. Increased D-dimer. DIC. Splenomegaly.	Steroids, antibiotics.	Recovery	No	CR	
Chinetal. <sup>35</sup> 2019 Australia	Secondary haemophagocyti c lymphohistiocyt osis due to checkpoint inhibitor therapy	Malignant melano ma	1	69 F	Metastatic	Nivo lu ma b (ma intenance)	lpilimumab/nivo lumab	HLH	Unclear	30	Fevers, lethargy, abdominal distention, swelling, Hepatosphenomegaly Anombocytopena, thrombocytopena, hypofibrinogenemia and hyperferritiermia, cD25 elevation, Reduced NK cell activity,	Stero ids	Recovery	No	SD	
Honjo et al <sup>1,8</sup> 2019 Japan	Severe cytokine release syndrome resulting in purpura fulmina ns despite successful response to nixolumab therapy in a patient with pleomorph is carcinoma of the lung: a case re port	Pulmonary pleomorphic carcinoma	1	52 F	Locally advanced (III)	Nivo lu ma b	Carboplatin + nab- pacltaxel (consolidation?)	CRS	'After the last nivolumab ad ministrati on.'	14	Asthenä, fever. Livedo reticularis with systemic purpura. Thrombocytopenia, increased serum solubie ILZ receptor, ferritin, trglyverides, LDH, CK. Myocarditis (increased CKMB). Gangrene of lower extremites, amputated.	Steroids, thrombomoduli n and my cophenolate mofetil, hemodiafiltrati on.	Recovery	No	PR	Paraneo plasti c syndrome prior to ICI initiation.
Adashek and Feki man <sup>37</sup> 2019 USA	Cyto kine Re la ase Synd ro me Result ing From Anti- Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists	Lung ade noca reino ma	1	72 M	Metastatic	Pe mbro lž uma b	Radiotherapy, carboplatin, pe metrexed	CRS	3 then again after 4	1	Fever, chills, and hypotension, mental status change the first time. Then hypotension, batic acticols, and respiratory distress.	Tocilizumab	Recovery	Unclear	Unclear	
Siota et al. <sup>38</sup> 2019 USA	Cyto kine Release Synd rome As a Rare Complication of Nivo luma b: A Case Report	Malignant melano ma	1	71 M	Metastatic (stage IV)	N ivo lu ma b		CRS	17	U nclear	Altered mental status, hypotension, tachycardia, fever, hypoxia. Grade 3 maculopapular rash.	Broad- spect rum ABs, steroids, tocilz umab	Recovery, then relapse 6 weeks later (deceased)	No	PR	
Takahashi etal. <sup>39</sup> 2020 Japan	A case of pembro iz uma b- ind uced hemo phagocytic lym pho histiocyt osis successfully treated with pulse glucocorticoid therapy	Lung ade noca reino ma	1	78 M	Metastatic (stage IV)	Pembrolž umab	Initially 2 cycles of carbopiatin and pemetrexed, then switch because of bacterial pleuritis.	HLH	1	7	High grade fever, liver dysfunction and diarrhea, hy pertriglycer dem a / hy pofibrino gene mia, e leva ted ferritin, he mophagocytos is in bone marrow, cy topenia and e levated IL-2R.	Prednisolone, antibiotics; later switch to i.v. methylpredniso lone.	Recovery	No	S D for 3 months	

11

Ohira et al. <sup>40</sup> 2020 Japan	A case report of fulm ina nt cytokine release syndro me complicated by dermato myositis after the com bination the rap with im mune checkpoint inhib tors	Renal cell carcino ma	1	78 M	Metastatic (stage IV)	Nivolu ma b and ipilim uma b		CRS	2	2	'Dermatomyositis [] high fever, hypotension, respiratory failure, impaired consciousness, renal failure, and coagulaton abnormality.'	Steroids, mycophenolate mofetil, plasma exchange; also in need of in tubation and dia lysis.	Recovery	No	SD for 2 months	
Normand et al. <sup>43</sup> 2020 Switzerland	Ac ute cyto kine release syndro me after a first dose of pembrolizumab a s second-line treatment for metastatic, programmed death-ling and 1- positive, no n- small-cell lung cancer	Lung adenoca rcino ma	1	79 M	Metastatic (stage IV)	Pembroik umab	Carboplatin, pemetrexed, denosumab, who le brain radiation.	CRS	1	1	High fever, renal impairment (lab results), elevated high-sensitivity troponin T, confusion, d'yspnoea.	Antibiotics, steroids.	Recovery	No	SD for 6 months	Acuteonset, which is rarely reported.
<b>Gaoeta</b> l. <sup>42</sup> 2020 China	An esophagea l cancer case of cytokine release syndro me with mu kiple-organ injury induced by an anti-PD-1 drug: a case report	Esophageal squamous cell carcinoma	1	69 M	Loca ly ad vanced	S intilima b	Docetaxel, neda platin, radiation.	CRS	3	Unclear; symptoms after 6 fractions of radiothera py (2 Gy per fraction).	' Fever, diarrhea, he matological inflammation, renal da mage and so on.'	Methylpredniso lone, tocilizumab, mycophenolate mofetil levothyroxine, and human immunogbouli n.	Recovery	Unclear	Unclear	
Özdemiret al. <sup>43</sup> 2020 Switzerland	Cyto kine directed t hera py with to cilizuma b for immune check point inhibitor related hemo phagocytic lympho histiocyt osis	Malignant melano ma	3 (1)	42 M	Metastatic (stage IV)	Ipilimu ma b/nivo l u ma b		HLH	2	Unclear	Fever, nausea, extreme fatigue and drowsiness. Pancytopenia, he pat Nis G3, disorder of coagulation- fibrinolys is system, AKIN III.	Systemic steroids, tocilizumab, plasma, low dose heparin prophylaxis.	Recovery	Unclear	CR	Good cytokine overview with suggestions for potential therapies.
Cont. Özdemiret al.		Malignant melano ma	3 (2)	36 M	Metastatic (stage IV)	N ivo lu ma b		HLH	5	U nclear	Splenomegaly. Deterioration of general condition, fever and extreme fatigue. Pancytopenia, hepatitis G3, disorder of coagulation- fibrinolys system.	Tocilizu mab, steroids, Iow dose heparin prophylaxis.	Recovery	Unclear	PR	
Cont. Özdemiret al.		Malignant melano ma	3 (3)	32 M	Metastatic (stage IV)	Ipilimu ma b/nivo l u ma b		HLH	3	U nclear	He patospleno megaly Deterioration of general condition, fever and extreme fatigue. Pancytopenia, he patitis G3, disorder of coagulation fibrinolys system.	Tocilizu mab, plasma, low dose heparin prophylaxis	Recovery	Unclear	PR	
<b>Azari et a I.</b> 44 2 02 0 UK	First case of hemo phagocytic lympho histio- cytosis secondaryto ca bozantinib with checkpo int inhibitors	Renal ce II carcino ma	1	54 M	Metastatic	Nivo luma b and ipilim uma b	Cabozantinib	HLH	1	6	"Myalgia, fevers, frontal headache, photophobia, blurry vision, and vormiting", later rash, oral ulceration, conjunctivitis and fever, accompanied by kidney failure and elevated liver enzymes, coagulopathy,	Initially Septrin and acyclovir for suspected meningits, upon deterioraton. Meropenem, followed by methylpredniso lone and anakinra.	Recovery	No	Unclear	

											ence phalitis.					
Dupré et a l.º5 2020 France	Ha emo phago- cytic lymphohistio- cytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review	Pulmonary sarcomatoid carcinoma	5 (1)	54 M	Metastatic	Pembrolž umab		HLH	1	7	Fever, asthenia, dyspnea, bone pain. Bitytopenia (thrombocytopenia, a nemia), hyppefreritinemia. Hemophagocytosis.	Steroids, broad- spectrum Abs.	Recovery	Yes	PD	Report of 5 cases from a pharmacovigi lance study.
Cont. Dupréetal.		Malignant melano ma	5 (2)	35 F	Metastatic	Ipilimu ma b/n ivo l u ma b		HLH	1	2 1	Ast henia, s ple no megaly, thro mbocyto pe nia. Hemophagocytos is . Hyperferrit inem ia, hy pofibrino gene mia, hy portibrino gene mia,	Steroids, etoposide, IV imm unogo buli ns, tocilizumab.	Recovery	Yes	SD	
Cont. Dupré et al.		Malignant melano ma	5 (3)	52 F	Metastatic	Ipilimumab/pem brolizumab		HLH	'After ipilimu mab perfusion .'	30	Asthenia, fever. Hepatic cytolysis. Pancytopenia, hypofibrinogenemia, hyperferrit inemia, hyperfeyteridemia. Hemophagocytosis. Cerebral hemorrhage.	Steroids, etoposide	Deceased	No	PD	
Cont. Dupré et al.		Malignant melano ma	5 (4)	69 M	Metastatic	Ipilimumab/nivol umab		HLH	'Five weeks and two cycles after the introductio n of the combinatio n.'	U nclear	Fever. Spleno megaly. Cytopena, hyperferritinema. Hepatic cytolysis, lymphocytic meningitis.	Stero ids	Recovery	Yes	PD	Several different combinations of ICIs and TKIs. Low HScore with other irAEs, diagnosed as HLH. No he mophago c yttosis.
Cont. <b>Dupré et al</b> .		Me lano ma	5 (5)	27 M	Stage III	Ipilimu ma b/n ivo l u ma b		HLH	Unclear	U nclear	Fever, anemia, hyperferritinemia. Hemophagocytosis. Hypophysits, lymphostyt: meningits, colitis, hepatic cytolysis.	Steroids	Recovery	No	Unclear	Received adjuvant pembrolizum ab, progressed, then ipilimumab/p embrolizuma b.
Akagiet al.⁴6 2020 Japan	He mo phagoc yt ic Lym pho histioc yt osis in a Patient with R he uma to id Arthritis on Pembrol izuma b for Lung Adenocarc ino ma	Lung ade noca reino ma	1	74 M	Locally ad vanced (stage 1118)	Pembro l2 uma b		HLH	1	27	Joint swelling, hypertension, fever 38.9°C, diffuse macular rash. Leukopenia, anemia, thrombocytopenia. High forthin level. High D-dimer. He patospleno megaly	Steroids, recombinant thrombomoduli n, G-CSF, etoposide.	Recovery	No	CR	Active rheumatoid arthritis.
Thummalap alli et al." 2020 USA	He mo phagocytic Lym pho histiocyt osis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glio blastoma	Glio blastoma	1	74 M	Unclear	N ivo lu ma b	Anti-IDO1 inhibitor	HLH	2	17	Elevated ASAT, ALAT, ALP, total bilirubin. Fever, altered mental status, leukopenia, neutropenia. Spleno megaly. Hyperferritinemi, IL- 6. Hypertriglyceridemia.	Steroids, vancomycin, ceftazidime, metronidazole, amphotericin B, acyclovir, and atovaquone.	Deceased	No	Unclear	

											-					
<b>Mizuta et</b> al. <sup>48</sup> 2 02 0 Ja pa n	He mo phagocytic lym pho histiocyt osis with adva need malig na nt me la no ma accompanied by ipilim uma b a nd nivo luma b: A	Malignant melano ma	1	69 F	Metastatic	Ipilimu ma b/n ivo l u ma b		HLH	2	1	Fever, malaise, headache, grade 2 diarrhea, thirst, elevated liver enzymes, elevated CRP and LDH. Thrombocytopenia, D-dimer elevation. Lymphadenopathy.	NSAID, levofloxacin, steroids	Unclear	Unclear	Unclear	
	case report and literature review															
Ceschiet	Interature review	Melanoma, lung	58	Med.	Unclear	Ipilimu ma b,	Co-suspected drugs	CRS	10 cases	"A median	"C RS, defined	No reported	Two fata I cases,	Unclear	Unclear	
al. <sup>16</sup> 2020 WHO database, inc. reports from N. America,	Check point Inhibitor- Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilan	cancer, other unspecified cancers	cases, 42 patients with non- hematol ogical maligna ncies.	age 55 y (inc. hem atolo gical cases ).		nivolumab, pembrolzumab, cemiplimab, atezolzumab, avelumaband combinations.	were antineoplastic agents in 18 cases and 5 other unspecified drugs.		aftera single ad ministrati on.	of 4 weeks after ICI initiation."	accordingly to the correspondent MedDRA T 'cyto kine release syndrome' (MedDRA version 21.1)."		unknown outcome in 20 cases			
Europe, Australia,	ce Database			34 M												
Japan.				21 F												
Kalmuk et al. <sup>49</sup> 2020 USA	Pembroliz uma b- ind uced Hemophagocytic Lymphohistiocyt osis : an immunotherape utic challenge	O ro pharyngeal squamo us ce ll carcinoma	1	61 M	Metastatic	Pe mbro lž uma b	Cis platin, radio therapy, as pirin/clopidogre I.	HLH	14	4	Fever, malaise, pancytopenia, transaminitis. He patospleno megaly . Hyperferritine mia, hy pofibrino gene mia, hypertriglyceride mia. Elevated slt-2 R.	Antibiotics, stenoids, etoposide	Recovery	Yes	S D for 8 months	
Huetal. <sup>50</sup>	Pulmo na ry	Colon	1	50	Metastatic	Sintilimab		Pulmonary fibrosis	2	1	Fever, hypotension,	IV fluids,	Recovery	Unclear	Unclear	P ulmo na ry
2 02 0 C hina	fibrosis and cytokine release syndrome after hyperactivation withsintilimab			М				with cytokine storm.			dyspnea, desaturation. Type I respiratory failure. Pulmonary ede ma and cardiogenic shock. Elevated D- dimer and BNP. Elevated IL-6 and IL- 10. Elevated CRP.	vasop ressors, stero kls, broad- spectrum ABs, nintedan ib.				fibrosis due to CRS. Previously received Nivolumab withoutirAE.
Nieves Borre ro et al. <sup>51</sup> 2 02 0 USA	Atezo lizu ma b associated with t umo r lysis syndro me, cytokine release syndro me, and autoimmune toxicity	S mall cell lung cancer	1	68 M	Metastatic	Atezolkumab	Carbo platin, etoposide	CRS	1	3	Acute kidney injury, elevated lactate, phosphorus, potassium, urcacid and LDH. Hypotension, cardiac arrest. Elevated IL-6, CRP, IP-V y and ferritin. Elevated ASAT/ALAT and bilirubin.	Hemodialysis, renal replacement therapy.	Deceased	No	Unclear	
Dudda et al. <sup>52</sup> 2020 Germany	He mo phago cytic lym pho hist locyt osis of a me lano ma patient und er B RAF/MEK- inhibitor thera py following anti- PDL inhibitor treat ment: a case report and review to the likerature	Malignant melano ma	1	Unci ear Unci ear	Metastatic (stage IV)	Nivo lu ma b	Dabrafenib/tra metinib after ICI progress.	HLH	Unclear	21	Elevated CRP, procacition in, splenomegaly, fever. Pancytopen 8. Hyperferifinem 8. increased sCD25 receptor, hypertrigk/cendemia, hypofibrinogenemia.	Broad- spectrum Abs.	Recovery	No, but rechallenge with vermurafenib and cobimetinib (different BRAF/MEKi).	PR	Sequential TKI and ICI.

Amlaniet al. <sup>93</sup> 2020 Canada	Successful Treatment of Cyto kine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune- Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature	Malignant melano ma	1	58 M	Metastatic (stage IV)	Nivo luma b	Dabrafe nib/tra metinib after IcI progress. Side effects, switched instead to vemurafen Ib/cobimeti nib.	CRS	Unclear	U nclear	Fatigue, malaise, and chills. Severe nausea, yomiting, diarrhea, fever of 39°C, and a purpuric eruption on his lower extremites. Distributive shock not responsive to fluids. Transaminitis, atrial fibrillaton. Oliguria acute kidney injury, wo sened a nema and thrombocyto pena, and confusion. NO hemophagocytosis. Encephab pathy. Acute as piration. Elevated IL-6, IL-10, IFMy, ThFa.	Broad- spectrum ABs, ste nids, tocileumab	Recovery	No	Unclear	TKI and ICI
Yomota et al. <sup>54</sup> 2 02 1 Japan	Cyto kine Re lease Synd rome Ind uced by Im mune- check point Inhibitor The ra py for Non-sma II-ce II Lung Cancer	Lung ade noca rcino ma	1	53 M	Metastatic (stage IV)	Atezo liz u ma b	Cis plat in, pe met rexed, rad lation .	CRS	1	7	"High fever, rash, DIC, reduced level of consciousness, heart failure with LVEF reduced to 20% from normal at baseline."	In itially methylpred niso lon e, tociliz umab from day 11; supportive therapy requiring vasop ressors.	Recovery	No	PR	
Perciket al. <sup>55</sup> 2021 Is rael	Capillary leak syndrome: an unrecognized early immune adverse effect of checkpoint- inhibitors treatment	Malignant melano ma	2 (1)	58 M	Stage IIIB	Nivoluma band ipilim uma b	No	Ca pillary-lea k synd ro me.	Nivolumab single	21	Generaliz ed e de ma	Discontinuation of ICI	Initial recovery, followed by severe proximal muscle weakness and death one month later.	No	PR	
Cont. Perciketal.		Duodenal adenocarcino ma	2 (2)	72 F	Stage II	Pembroliz umab and 'an investigational CTLA-4 bbcker.'	Unclear if combined	Ca pillary-lea k s ynd ro me.	FO LFOX initially, then 5 FU, irinotecan and be vacizu ma b and radiation at time of relapse.	1	Fever, fa tigue, bilateral leg swelling weight gain.	Steroids	Recovery	Unclear	Unclear	
De I Be IIo et al. <sup>56</sup> 2 02 1 France	Cytokinestorm induced by PD1 inhibitor in a renal transplant patient	SCC	1	81 M	Unckear	Cemiplima b	Tacrolimus, mycophenolicacid, steroids (reduced doses)	Cytokine storm, rejection of renal graft.	1	7	Septic shock (unclear specific symptoms), renal failure.	Steroids	Dialysis, kidney necrosis transplantecto my. complications after surgery leading to death.	No	Unclear	Acute rejection of renal transplants after ICI.
Sac kate in et al. <sup>577</sup> 2021 USA	Pembroliz uma b- induced cytokine rolease syndrome in a patient with metastatic lung adenocarcinoma : a case report	Lung ade noca rcino ma	1	55 M	Metastatic	Pe mbro iz uma b	Pemetrexed, carbopla tin, SRS of brain.	CRS	3	19	Fever, chills, hypotension, tachypnea, lethargy, Elevated inflarmatory markers (ferrtin, erythio cyte sedimentation rate and C reactive protein) as wellas elevated LDH, serum amino-transferases, actue kidney injuy, a bsolute lymphocyto pena with normal hermoglobin and	Vas opressors, IV fluids, broad- spect rum ABs, stem ds, vermed in, hemod la lysis, tocile u ma b	Recovery	Unclear	Unclear	

											platelet count, and moderate neutropenia. Elevated IL-6. Encephalopathy with aphasia and somnolence.					
O liva res- Hernández et al. <sup>58</sup> 2021 Spain	Response to Treatment with a n Anti- Interle ukin-6 Receptor Antibody (Tocilizumab) in a Patient with He mophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors	C horoida I me la noma	1	F	Metastatic	Ipilim uma b		HLH	3	U nclear	Thrombocytopenia. Splenomegaly. Hyperfertinemia, hypofithiongenemia, anemia.Fever, elwation of CRP. Elevated IL-2.	Steroids, tocilizumab.	Recovery	Unclear	PR	P re vio us ly received nivo lu ma b.
Kurozumi et al. <sup>59</sup> 2 02 1 Japan	Two cases of lung cancer with hemophagocytic lym pho histiocyt osis caused by im mune check point in hibitors	Lung ade noca rcinoma	2 (1)	75 M	Metastatic	Pembro le uma b		HLH	1	10	Fever, elevated liver enzymes, cytopenia, coagulopathy, hyperferritinemia.	Steroids	Unclear	Unclear	Unclear	
Cont. Kurozumi et al. <sup>59</sup>		Lung adenoca rcino ma	2 (2)	60 F	Loca Ily ad vanced (IIIB)	Pembro lž uma b	Pemet rexed, chemotherapy (?)	HLH	'After last dose of pe mbro liz u ma b.'	30	Cytopenia, coagulation abnormalities, and elevated liver enzyme levels, hyperferritinemia.	Stero ids	Unclear	Unclear	Unclear	
Masood et al. <sup>40</sup> 2021 USA	Secondary hemophagocytic lymphohisticocyt osis due to nivoluma b/ipili mu ma b in a renal cell cancer patient — A case report	Renal carcino ma	1	68 M	Metastatic	Ipilmu mab/nivol u mab		HLH	"Maintenan ce nivolumab."	Unclear	Decreased appetite, dzziness, generalized weakness, and declining performance status. Intermittent fevers with associated tachycardia. Symptomatic hyporterritinemä, hyporfirringenemä, hypofirringenemä, bw NK cell activity, sc D25 elevation. Spieno megaly. NO hemopha gocytos is.	Stero ids	Recovery	Unclear	Unclear	
Pachokzak- Madejet al. <sup>61</sup> 2021 Poland	Effective Treatment of a Me is no ma Patient with Hemophago- cytic Lympho hist is o- cytosis after Nivo luma is and Ipilimuma b Combined Immunotherapy	Malignant melano ma	1	57 F	Metastatic	Ipilimu mab/nivo l u mab		HLH	4	U nclear	Fever, general mala &c, dyspnea at rest and elwated markers of inflarmation and LDH. Elwated CRP and procalcitonin. DIC: Hyperferrti inernä, by pofibrino genernia, bw a PTT, high INR. Hypertriglyceridemia. Splenomegaly.	S tero ids., FFP, myco pheno late mofe til, cyclophos pham id e, eto poside, cyc b sporin.	Recovery	No	PR	Radiotherapy after PR.

Tiu et al. <sup>∞</sup>	A Wolf in Sheep's	NSC LC	3 (1)	59	Metastatic	Unclear		HLH	1	11	Fever, rigors, lymphopenia,	Broad- s pect rum ABs,	Recovery	Unclear	Unclear	
2 02 1 U K	Clothing: Systemic Immune Activation Post Immunotherapy			F							thrombocytopena, elevated LDH, elevated transaminases, hypertriglyceridemia, hyperferitinemia, hemophagocytosis.	steroids, PPIs.				
Cont. Tiu et al.≊		Breast cancer	3 (2)	42 F	Metastatic	Unclear		HLH	1	11	Fever, macub papu brrash, thrombocytopen a, elevated LDH, transaminitis, hypertrglyceridemia. Normal ferrtlin, then hyperferrtlinemia 3 days after first fever episode. Dyspnea, hypoxia.	Broad- spectrum ABs, steroids, PPIs, tocilizumab.	Recovery	Unclear	Unclear	
Cont. Tiu et al.≊		Bladder cancer	3 (3)	67 M	Metastatic	Unclear		HLH	1	10	Fever, rigors, thrombocytopena, lymphopenia, hyperferritinema. Respiratory failure (type 2). Hemophagocytosis. Elevated II: 2, IL-6, IL- 8, IL-10, IFNY, TNFoc.	Broad- spectrum ABs, sten ids, tocilizumab, anakinra, hemofiltration, therapeutic plasma exchange, IV immunogb buli ns.	Recovery	Unclear	Unclear	
Ta yet al. <sup>54</sup> 2022 Singa pore	Cyto kine Release Syndro me in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Litenture	NSCLC, renal cell carcinoma, hepatoellular carcinoma, melanoma.	25	Med. age 64 18 M 7 F	Metastatic (stage IV)	Pembrolizumab, nivolumab, ipilimumab, anti- LAG3-antibody.	Concomitant che motherapy: 6, concomitant radiation: 4, concomitant TKI: 4.	CRS		Median of 11days after ICI initiation.	All had fever of 38°C or higher.	Steroids, tocilzumab	3 fatal (of those who received tocilizumab, uncear if more).	in 7 patients, no grade 3/4 events.	PR:6,SD: 5,PD:10	Out of n=539 patients receiving ICIs, correspondin g to 4.6% of all ICI treated patients.
Zhang et al. <sup>63</sup> 2022 China	Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with <i>EGFR</i> -mutated non-small-cell lung cancer: A case report	Lung adenoca rcino ma	1	67 F	Metastatic	Pembrolz umab		CRS	Unclear	1	Fever, nausea, vomiting, and chest pain. CR and por calcitonin elevation. Hypotension, hypotension, tachycard a, and rash. Transaminase elevation, acute kdiney injury, and disseminated intravascular coaguistion. T cell	Broad- spectrum Abs, IV fluids, oxygen, steroids.	Recovery	No	PR	

### Discussion

CRS and HLH are potentially life-threatening side effects of treatment with ICIs; however, they are relatively rare and therefore are challenging to study. In this systematic review, we provide a comprehensive picture of the reported cases in the literature to date. Our results underscore the notion that hyperinflammatory syndromes are rare, often treatable, and rarely fatal (**Table 1**).

It is interesting to note the predominance of male patients in both case reports and small case series, as well as in pharmacovigilance databases. This might partly be driven by a higher proportion of men among lung cancer patients<sup>64</sup>, which represent the second largest tumor group in the identified studies, and partly by sex differences in the immune response<sup>65</sup>. Interestingly, pharmacovigilance data suggest that the outcome of CRS is more favorable in females than in males<sup>16</sup>, warranting further research into sex differences in response to treatment and in side effect profiles of ICIs.

Wider indications and lower costs have continuously led to higher numbers of patients being treated with ICIs. Hence, the clinical need to understand rare side effects has increased, and higher patient numbers allow more informed clinical decisions. A common clinical dilemma in patients receiving ICIs is whether to continue treatment despite severe, and potentially life-threatening irAEs. Key factors in this decision-making process are the risk of recurrence of a given irAE, the anticipated severity in case of recurrence, as well as its treatability. A recent study has suggested that IL-6 blockade given in parallel with ICIs ameliorates irAEs, while enhancing the antitumoral effect of ICIs<sup>66</sup>. Earlier experimental data had already hinted at the potential benefit of adding IL-6 inhibitors to ICIs in mouse models of pancreatic cancer<sup>67</sup> (which is largely resistant to ICI therapy), as well as hepatocellular carcinoma<sup>68</sup>. Together, these data suggest that IL-6 blockade does not abrogate, but rather enhances, the activation of a beneficial antitumoral immune response, providing a potential oncological rationale for combining IL-6 inhibition and ICIs. Results from CAR-T cell therapy in hematological malignancies support the lack of antagonistic effects of IL-6 antagonists in combination with ICIs; for example, in refractory large B-cell lymphoma, response rates to CAR T cell therapy were independent of the use of concomitant tocilizumab to treat CRS<sup>69</sup>.

Our review of the literature revealed that IL-6 inhibitors have successfully been used in cases of hyperinflammatory irAEs upon ICI treatment (**Table 1**). Given the evidence that combined anti-IL-6/ICI treatment enhances the antitumoral effect and is highly effective for

CRS, an important open question is whether a rechallenge after mild CRS/HLH that responded well to anti-IL-6 treatment or corticosteroids should be considered. As shown in **Table 1**, only a few case reports exist on ICI rechallenge after CRS or HLH: One patient with metastatic oropharyngeal squamous cell carcinoma developed HLH after cycle 14 of pembrolizumab and was successfully treated with dexamethasone and etoposide<sup>49</sup>. Eight months after this episode, during which no treatment was given, tumor progression was noted, and the patient was restarted on pembrolizumab without signs of recurrent HLH after five additional cycles<sup>49</sup>. Another patient with a locally advanced lung adenocarcinoma developed CRS after the first cycle of pembrolizumab as first-line treatment, and was successfully treated with methylprednisolone<sup>31</sup>. Pembrolizumab was restarted while the patient was on low dose oral corticosteroids; the patient experienced no relapse of CRS and showed a near-complete tumor response to pembrolizumab<sup>31</sup>.

As a higher tumor burden has been shown to correlate with increased inflammation parameters and cytokine levels<sup>70</sup>, it can be hypothesized that pre-treatment tumor burden is associated with the risk of developing irAEs. Indeed, studies of CAR T cell treatment for B cell acute lymphoblastic leukemia (B-ALL) have shown a significant correlation between severe CRS and a high tumor burden<sup>71,72(p19)</sup>. In the largest case series published containing n = 25 cases, n = 7 were cases after rechallenge with ICIs; none of these had grade 3 or 4 CRS<sup>14</sup>, which lends some support for continuous ICI treatment despite CRS and could be appropriate in selected cases, as the risk of aggravated side effects when re-exposing patients to ICIs could be low.

While we mostly found case reports, two studies reported pharmacovigilance data from the global WHO database, and two reports queried the Registry of Severe Adverse Reactions to Immunomodulatory Antibodies used in Oncology (REISAMIC), a database for ICI-related irAEs in France<sup>24,45</sup>. The first report on REISAMIC data included n = 16 patients with "fever reaction" to ICI treatment, and based on their analysis of these cases, the authors concluded that this irAE can "usually be controlled with a short course of corticosteroids". The second report also queried two other French databases specifically for HLH cases, and identified n = 5 patients with HLH, one of which was fatal. In n = 3 of the five cases, rechallenge of ICI was reported, in n = 2 cases without recurrence of fever of HLH<sup>45</sup>. One of the HLH cases was identified in REISAMIC among n = 745 patients included "at a single center between 2014 and 2019", suggesting that HLH indeed is a rare event. The rarity of HLH is also supported by the analysis of WHO pharmacovigilance data: 49,883 ICI-related adverse events were retrieved from the WHO database VigiBase on a search conducted in

September 2018, n = 38 of whom corresponded to HLH, and n = 34 were directly linked to ICI treatment, usually developing more than six weeks after ICI treatment. Interestingly, the rate of other irAEs was below 20%<sup>15</sup>. The same group of authors queried VigiBase for CRS as of January 2020. They found n = 58 reports likely corresponding to CRS among a total of 80,700 reports on ICI-related adverse events, of which n = 43 were definitely related to ICIs, and which occurred a median of approximately four weeks after initiation of ICI treatment<sup>16</sup>. Two of those cases were fatal. Finally, a recent study presented a case series collected at two hospitals in Singapore between February 2014 and January 2021. They found that n = 25 out of a total of n = 539 patients that had received ICI developed CRS, which is a considerably higher frequency than suggested by the pharmacovigilance data, and the reason for this difference is unclear. In this cohort, n = 7 patients with low grade CRS were rechallenged with ICIs and did not relapse. A total of n = 3 cases had fatal CRS despite tocilizumab treatment<sup>14</sup>. The authors also suggested that time-to-fever-onset, low platelet count and high urea levels at CRS presentation might serve as indicators of a severe course <sup>14</sup>.

Although several studies have reported an association between irAEs and improved treatment outcome<sup>73,74</sup>, it is still debatable whether ICI rechallenge after irAEs might be oncologically favorable. In accordance with current guidelines, the majority of patients with grade 3 or 4 irAEs will discontinue treatment with ICI permanently. The rarity of cases, resulting in cohorts of limited size, poses a challenge when addressing the question of ICI rechallenge. While recent studies have shown that rechallenge with ICI after irAE does not significantly improve overall survival<sup>75</sup>, others have concluded that irAEs upon rechallenge display milder toxicities, and suggested that rechallenge might be safe for most patients, depending on the type of irAE<sup>76,77</sup>. Furthermore, a meta-analysis of patients with non-small cell lung cancer rechallenged with ICIs suggests that certain patients with disease progression during ICI discontinuation might benefit from ICI rechallenge<sup>78</sup>. Whether these data are applicable to ICI-related CRS remains to be seen.

In summary, the published data suggest that CRS and HLH are infrequent, potentially severe, but frequently treatable side effects of ICIs, and that rechallenge could be considered in selected cases, with IL-6 inhibition as an attractive preventive and therapeutic option.

#### **Declarations**

#### Availability of data and material

Data are available from the authors upon request.

## **Competing interests**

The authors declare no competing interests.

# Funding

This study received no dedicated funding. MG is supported by The Swedish Research Council (grant number 2018-02023), LLL is supported by The Swedish Society of Medicine and Swedish Society for Medical Research (grant number P17-0134).

## Authors' contributions

LLL and MG conceived the study and performed the literature search together with the librarians of Karolinska Institute's library. LLL, MS, and MG decided on study inclusion and collected the data for the systematic review. LLL, MG, and UH collected and interpreted the data from the clinical case. MG wrote the manuscript, LLL, MS, and UH edited the manuscript.

# Acknowledgements

The authors are grateful to Narcisa Hannerz and Sabina Gillsund of the Karolinska Institute's Library, for expert help in conducting the systematic literature search. We are grateful to Marie Meeths for advice on the manuscript.

## References

1. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv119–iv142. doi:10.1093/annonc/mdx225

2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update | Journal of Clinical Oncology. [accessed June 15, 2022]. https://ascopubs.org/doi/full/10.1200/JCO.21.01440

3. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi:10.1182/blood.2018894618

4. Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evidence-Based Medicine. 2018;23(1):6–6. doi:10.1136/ebmed-2017-110885

5. Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622320976996. doi:10.1177/2040622320976996

6. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–e127. doi:10.1016/j.bbmt.2018.12.756

7. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96. doi:10.1038/s41577-021-00547-6

8. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23(8):943–947. doi:10.1634/theoncologist.2018-0028

9. Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705–714. doi:10.2147/TCRM.S223468

10. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. doi:10.1002/art.38690

11. Meeths M, Bryceson YT. Genetics and pathophysiology of haemophagocytic lymphohistiocytosis. Acta Paediatrica. 2021;110(11):2903–2911. doi:10.1111/apa.16013

12. Sharma N, Stroud CRG, Walker PR, Cherry CR, Cherukuri SD, Addepalli S, Parent T, Hardin J. Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors. JCO. 2016;34(15\_suppl):3061–3061. doi:10.1200/JCO.2016.34.15\_suppl.3061

13. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–243. doi:10.3163/1536-5050.104.3.014

14. Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst A-M, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A, et al. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. Front Immunol. 2022;13:807050. doi:10.3389/fimmu.2022.807050

15. Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019;7(1):117. doi:10.1186/s40425-019-0598-9

16. Ceschi A, Noseda R, Palin K, Verhamme K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020;11:557. doi:10.3389/fphar.2020.00557

17. Henter J-I, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi:10.1002/pbc.21039

18. Henter J-I, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–2373. doi:10.1182/blood-2002-01-0172

19. Rassy EE, Assi T, Rizkallah J, Kattan J. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy. 2017;9(4):309–311. doi:10.2217/imt-2016-0134

20. Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28(6):1403. doi:10.1093/annonc/mdx113

21. Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64(12). doi:10.1002/pbc.26642

22. Urosevic-Maiwald M, Mangana J, Dummer R. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Annals of Oncology. 2017;28(7):1673–1675. doi:10.1093/annonc/mdx187

23. Takeshita M, Anai S, Mishima S, Inoue K. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Annals of Oncology. 2017;28(1):186–189. doi:10.1093/annonc/mdw537

24. Michot J-M, Pruvost R, Mateus C, Champiat S, Voisin A-L, Marabelle A, Lambotte O. Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. Ann Oncol. 2018;29(2):518–520. doi:10.1093/annonc/mdx701

25. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report - PMC. [accessed June 21, 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989389/

26. Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018;6(1):73. doi:10.1186/s40425-018-0384-0

27. Satzger et al Treatment-related hemophagocytic lymphohistiocytosissecondary to checkpoint inhibition with nivolumab plusipilimumab - Google Suche. [accessed June 21, 2022]. https://www.google.com/search?q=Satzger+et+al+Treatment-related+hemophagocytic+lymphohistiocytosissecondary+to+checkpoint+inhibition+with+niv olumab+plusipilimumab&rlz=1C5GCEM\_en&oq=Satzger+et+al%09Treatment-related+hemophagocytic+lymphohistiocytosissecondary+to+checkpoint+inhibition+with+niv olumab+plusipilimumab&aqs=chrome..69i57.317j0j4&sourceid=chrome&ie=UTF-8

28. 168 A Case of Epstein-Barr Virus-Related Hemophagocytic Lymphohistiocytosis in Association With Pembrolizumab Therapy - ProQuest. [accessed June 21, 2022]. https://www.proquest.com/openview/ccce829a40174af9e581abea320c369b/1?pq-origsite=gscholar&cbl=586299

29. Sasaki K, Uehara J, Iinuma S, Doi H, Honma M, Toki Y, Ishida-Yamamoto A. Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma. Ann Oncol. 2018;29(7):1602–1603. doi:10.1093/annonc/mdy175

30. Laderian B, Koehn K, Holman C, Lyckholm L, Furqan M. Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors. J Thorac Oncol. 2019;14(4):e77–e78. doi:10.1016/j.jtho.2018.11.035

31. Kogure Y, Ishii Y, Oki M. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non–Small Cell Lung Cancer Treated with Pembrolizumab. Journal of Thoracic Oncology. 2019;14(3):e55–e57. doi:10.1016/j.jtho.2018.11.025

32. Oda H, Ishihara M, Miyahara Y, Nakamura J, Kozuka Y, Iwasa M, Tsunoda A, Yamashita Y, Saito K, Mizuno T, et al. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Rep Oncol. 2019;12(1):147–156. doi:10.1159/000496933

33. Lorenz G, Schul L, Bachmann Q, Angermann S, Slotta-Huspenina J, Heemann U, Küchle C, Schmaderer C, Jäger M, Tauber R, et al. Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids. Rheumatology (Oxford). 2019;58(6):1106–1109. doi:10.1093/rheumatology/key447

34. Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y, Minami D, Sato K, Shibayama T. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med. 2019;58(5):699–702. doi:10.2169/internalmedicine.1001-18

35. Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy. Eur J Cancer. 2019;115:84–87. doi:10.1016/j.ejca.2019.04.026

36. Honjo O, Kubo T, Sugaya F, Nishizaka T, Kato K, Hirohashi Y, Takahashi H, Torigoe T. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7(1):97. doi:10.1186/s40425-019-0582-4

37. Adashek ML, Feldman M. Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists. J Oncol Pract. 2019;15(9):502–504. doi:10.1200/JOP.19.00160

38. Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report | Blood | American Society of Hematology. [accessed June 21, 2022]. https://ashpublications.org/blood/article/134/Supplement\_1/5630/425558/Cytokine-Release-Syndrome-As-a-Rare-Complication

39. Takahashi H, Koiwa T, Fujita A, Suzuki T, Tagashira A, Iwasaki Y. A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy. Respir Med Case Rep. 2020;30:101097. doi:10.1016/j.rmcr.2020.101097

40. Ohira J, Kawamoto M, Sugino Y, Kohara N. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore). 2020;99(15):e19741. doi:10.1097/MD.000000000019741

41. Normand CV, Zender HO, Staehli DM, Chouiter-Djebaili AF, John G. Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer. J Oncol Pharm Pract. 2021;27(6):1528–1533. doi:10.1177/1078155220980813

42. An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report - Gao - Annals of Palliative Medicine. [accessed June 21, 2022]. https://apm.amegroups.com/article/view/47672/html

43. Özdemir BC, Latifyan S, Perreau M, Fenwick C, Alberio L, Waeber G, Spertini F, de Leval L, Michielin O, Obeid M. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. Ann Oncol. 2020;31(12):1775–1778. doi:10.1016/j.annonc.2020.08.2101

44. Azari AE, Stratton R, Singh A. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors. Rheumatology. 2021;60(5):e167–e168. doi:10.1093/rheumatology/keaa750

45. Dupré A, Michot J-M, Schoeffler A, Frumholtz L, Baroudjian B, Delyon J, Lebbe C, Lambotte O. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. British Journal of Haematology. 2020;189(5):985–992. doi:10.1111/bjh.16630

46. Akagi Y, Awano N, Inomata M, Kuse N, Tone M, Yoshimura H, Jo T, Takada K, Kumasaka T, Izumo T. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma. Intern Med. 2020;59(8):1075–1080. doi:10.2169/internalmedicine.3889-19

47. Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma - FullText - Case Reports in Oncology 2020, Vol. 13, No. 2 - Karger Publishers. [accessed June 21, 2022]. https://www.karger.com/Article/FullText/507281

48. Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, Yamazaki N. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatologic therapy. 2020. doi:10.1111/dth.13321

49. Kalmuk J, Puchalla J, Feng G, Giri A, Kaczmar J. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge. Cancers Head Neck. 2020;5:3. doi:10.1186/s41199-020-0050-3

50. Hu J, Li Y, Chen X, Luo C, Zuo X. Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab. Journal of Clinical Pharmacy and Therapeutics. 2020;45(6):1474–1477. doi:10.1111/jcpt.13217

51. Nieves-Borrero K, Adler S, Pow-anpongkul P, Yeh J. ATEZOLIZUMAB ASSOCIATED WITH TUMOR LYSIS SYNDROME, CYTOKINE RELEASE SYNDROME, AND AUTOIMMUNE TOXICITY. In: AMERICAN JOURNAL OF KIDNEY DISEASES. Vol. 75. WB SAUNDERS CO-ELSEVIER INC 1600 JOHN F KENNEDY BOULEVARD, STE 1800 ...; 2020. pp. 613–613.

52. Dudda M, Mann C, Heinz J, Schmidgen I, Weid F, Kühn M, Saloga J, Grabbe S, Loquai C. Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature. Melanoma Res. 2021;31(1):81–84. doi:10.1097/CMR.000000000000703

53. Amlani A, Barber C, Fifi Ahah A, Monzon J. Successful Treatment of Cytokine Release Syndrome with IL 6 Blockade in a Patient Transitioning from Immune Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature. Oncologist. 2020;25(7):e1120–e1123. doi:10.1634/theoncologist.2020-0194

54. Yomota M, Mirokuji K, Sakaguchi M, Kitahara Y, Chin F, Setoguchi K, Hosomi Y. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer. Intern Med. 2021;60(21):3459–3462. doi:10.2169/internalmedicine.5922-20

55. Percik R, Nethanel A, Liel Y. Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment. Immunotherapy. 2021;13(8):653–659. doi:10.2217/imt-2020-0332

56. Del Bello A, Zakaroff AG, Meyer N, Delas A, Faguer S, Kamar N, Belliere J. Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. American Journal of Transplantation. 2021;21(7):2616–2618. doi:10.1111/ajt.16589

57. Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021;9(7):e002855. doi:10.1136/jitc-2021-002855

58. Olivares-Hernández A, Figuero-Pérez L, Amores Martín MA, Bellido Hernández L, Mezquita L, Vidal Tocino MDR, López Cadenas F, Gómez-Caminero López F, Escala-Cornejo RA, Cruz Hernández JJ. Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. Case Rep Oncol Med. 2021;2021:6631859. doi:10.1155/2021/6631859

59. Kurozumi A, Takahashi H, Watanabe T, Iwasaki Y. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors. Thorac Cancer. 2021;12(10):1625–1628. doi:10.1111/1759-7714.13954

60. Masood A, Wahab A, Clifford T, Weaver EJ, Ehsan H, El Ayass W. Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report. Clinical Case Reports. 2021;9(12):e05184. doi:10.1002/ccr3.5184

61. Pacholczak-Madej R, Grela-Wojewoda A, Lompart J, Żuchowska-Vogelgesang B, Ziobro M. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy. Prague Med Rep. 2022;123(1):35–42. doi:10.14712/23362936.2022.4

62. Tiu C, Shinde R, Pal A, Biondo A, Lee A, Tunariu N, Jhanji S, Grover V, Tatham K, Gruber P, et al. A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. J Immunother Precis Oncol. 2021;4(4):189–195. doi:10.36401/JIPO-21-9

63. Zhang M, Cheng Y, Hu Y, Nie L. Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report. Thorac Cancer. 2022;13(9):1419–1422. doi:10.1111/1759-7714.14390

64. Chen X, Mo S, Yi B. The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories. BMC Public Health. 2022;22(1):987. doi:10.1186/s12889-022-13281-y

65. Sex differences in immune responses | Nature Reviews Immunology. [accessed June 28, 2022]. https://www.nature.com/articles/nri.2016.90

66. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel S-E, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509-523.e6. doi:10.1016/j.ccell.2022.04.004

67. Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320–332. doi:10.1136/gutjnl-2016-311585

68. Liu H, Shen J, Lu K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Biochem Biophys Res Commun. 2017;486(2):239–244. doi:10.1016/j.bbrc.2017.02.128

69. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell

Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447

70. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi:10.1126/scitranslmed.3008226

71. Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183(3):364–374. doi:10.1111/bjh.15644

72. Li M, Xue S-L, Tang X, Xu J, Chen S, Han Y, Qiu H, Miao M, Xu N, Tan J, et al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Sci Rep. 2022;12(1):378. doi:10.1038/s41598-021-04296-3

73. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8

74. Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134. doi:10.1016/j.ctrv.2020.102134

75. Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? Cancers (Basel). 2021;13(5):989. doi:10.3390/cancers13050989

76. Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat M-C, Puyade M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade  $\geq 2$  immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8(2):e001622. doi:10.1136/jitc-2020-001622

77. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane A-F, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2020;6(6):865–871. doi:10.1001/jamaoncol.2020.0726

78. Xu S, Shukuya T, Tamura J, Shimamura S, Kurokawa K, Miura K, Miyawaki T, Hayakawa D, Asao T, Yamamoto K, et al. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep. 2022;3(4):100309. doi:10.1016/j.jtocrr.2022.100309